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Nonnucleoside reverse transcriptase inhibitors (NNRTIs) target HIV-1 reverse transcriptase (RT) by binding to a pocket
in RT that is close to, but distinct, from the DNA polymerase active site and prevent the synthesis of viral cDNA. NNRTIs,
in particular, those that are potent inhibitors of RT polymerase activity, can also act as chemical enhancers of the
enzyme’s inter-subunit interactions. However, the consequences of this chemical enhancement effect on HIV-1
replication are not understood. Here, we show that the potent NNRTIs efavirenz, TMC120, and TMC125, but not
nevirapine or delavirdine, inhibit the late stages of HIV-1 replication. These potent NNRTIs enhanced the intracellular
processing of Gag and Gag-Pol polyproteins, and this was associated with a decrease in viral particle production from
HIV-1-transfected cells. The increased polyprotein processing is consistent with premature activation of the HIV-1
protease by NNRTI-enhanced Gag-Pol multimerization through the embedded RT sequence. These findings support the
view that Gag-Pol multimerization is an important step in viral assembly and demonstrate that regulation of Gag-Pol/
Gag-Pol interactions is a novel target for small molecule inhibitors of HIV-1 production. Furthermore, these drugs can
serve as useful probes to further understand processes involved in HIV-1 particle assembly and maturation.
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Introduction
The HIV-1 reverse transcriptase (RT) is responsible for the
conversion of the viral single-stranded genomic RNA into a
double-stranded proviral DNA precursor. This process is
catalyzed by the RNA- and DNA-dependent polymerase and
ribonuclease H activities of the enzyme. HIV-1 RT is an
asymmetric dimer that consists of a 66- (p66) and a p66-
derived 51-kDa (p51) subunit [1]. The RT heterodimer is the
biologically active form of the enzyme; monomeric subunits
are devoid of polymerase activity [2,3].
The HIV-1 RT is translated as part of a 160-kDa Gag-Pol
polyprotein (Pr160gag-pol), which consists of the gag-encoded
structural proteins matrix (MA, p17), capsid (CA, p24),
nucleocapsid (NC, p7), and the pol-encoded viral enzymes,
the protease (PR, p10), reverse transcriptase (RT, p66/p51),
and integrase (IN, p31). A transframe region links the Gag
and Pol domains and consists of an N-terminal octapeptide
and p6pol [4]. The pol open reading frame partially overlaps
with gag and is translated by a ribosomal frameshifting
mechanism, which occurs in one out of 20 Gag translation
events [5]. This ensures the strict maintenance of a 20:1 ratio
of Gag to Gag-Pol that is important for viral assembly,
replication, and the production of infectious virions [6].
During or subsequent to virus budding, the viral PR auto-
activates and cleaves Gag and Gag-Pol into the structural and
viral proteins, which results in the maturation of immature
particles to form infectious virions [7].
While HIV-1 PR activation is a critical step in the viral life
cycle, the processes required for PR activation in HIV-1-
infected cells is not well defined [7,8]. It is thought that Gag-
Pol multimerization during viral assembly leads to activation
of the HIV-1 PR by dimerization of PR regions on separate
Gag-Pol polyproteins, followed by the autocatalytic cleavage
and release of a functionally active PR homodimer [7].
Although direct multimerization of Gag-Pol has not been
demonstrated biochemically, several domains within Gag-Pol
have been shown to influence PR activation including regions
that are proximal to the C- and N-termini of PR [9–13]. If
Gag-Pol dimerizes, as predicted, then HIV-1 RT, due to its
size and propensity to dimerize, is likely to contribute to Gag-
Pol dimerization and promote PR activation. In support of
this notion, deletions or C-terminal truncations of the RT in
the context of Gag-Pol leads to decreased processing of Gag
and Gag-Pol and impaired virus maturation [9,11,14]. There-
fore, the proper regulation of Gag and Gag-Pol processing is
an essential step in the production of mature viral particles.
Nonnucleoside reverse transcriptase inhibitors (NNRTIs)
are a chemically diverse group of lipophilic compounds that
comprise over 30 different classes and specifically inhibit
HIV-1, but not HIV-2 RT [15]. NNRTIs bind to an allosteric
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pocket in the p66 subunit of the RT and inhibit DNA
synthesis reactions by a non-competitive mechanism of
action [16,17]. Currently, three NNRTIs, namely nevirapine
(NVP) [18], delavirdine (DLV) [19], and efavirenz (EFV) [20]
have been approved for the treatment of HIV-1. However, the
genetic threshold of resistance for all three of these drugs is
low [21,22]. In this regard, the next generation of NNRTIs,
such as TMC120-R147681 (dapivirine) and TMC125-R165335
(etravirine), are more promising and are active against a wide
selection of NNRTI-resistant viruses [20,23,24]. Whereas EFV,
TMC120, and TMC125 are potent inhibitors of HIV-1
replication, NVP and DLV have 50% inhibitory concentra-
tions for HIV-1 replication that are at least 10-fold higher
[15,20,23,25].
While inhibitors of HIV-1 RT have been successfully used
to treat HIV-1-infected individuals, the emergence of strains
with reduced susceptibility to these drugs is an inevitable
consequence of their use [26]. Therefore, it is necessary to
identify new classes of HIV-1 inhibitors. Protein–protein
interactions are necessary for many viral processes that can
be targeted by peptides or small molecules [27]. We and
others have proposed that modulation of RT dimerization is a
potential drug target [2,28]. Since the HIV-1 RT is expressed
as part of the Gag-Pol polyprotein, it is conceivable that a
molecule that modulates RT subunit interaction can also
affect Gag-Pol/Gag-Pol interaction by binding to the embed-
ded RT sequence, which could promote activation of the
HIV-1 PR and viral polyprotein processing.
We and others have previously demonstrated that potent
NNRTIs, such as EFV, act as chemical enhancers of HIV-1 RT
heterodimerization, whereas other NNRTIs have little (NVP)
or no effect (DLV) [29,30]. EFV also significantly enhances
p66 homodimerization and the kinetics of processing of a
model 90-kDa Pol precursor protein by the Pol-embedded
HIV-1 PR [31]. These data prompted us to hypothesize that
EFV can affect Gag-Pol processing and possibly the late stages
of HIV-1 replication. The current study was designed to
address this hypothesis. Here we show that EFV, TMC120, and
TMC125, but not NVP or DLV, can enhance intracellular Gag
and Gag-Pol processing and decrease viral particle produc-
tion in HIV-1-transfected 293T and HeLa cells. This is the
first time that a small molecule inhibitor has been shown to
impact on the late stage of virus replication by enhancing
intracellular viral protein processing, and may provide the
basis for the design of inhibitors that target this stage of the
viral life cycle. Furthermore, these drugs can serve as useful
probes to further understand processes involved in viral
particle assembly and maturation.
Results
NNRTI Enhancement of p66 Homodimer Formation In
Vitro
We have previously demonstrated that the potent NNRTI,
EFV, enhances p66 homodimerization in vitro [31]. To
determine whether NVP, TMC120, and TMC125 also enhance
p66 homodimerization, purified recombinant hexa-histidine
tagged p66 (His-p66) was incubated in the presence of a 10-
fold molar excess of NNRTI with respect to total protein, and
analyzed by size exclusion chromatography (SEC). EFV was
used as a control. Consistent with previous studies, EFV
shifted the monomer-homodimer equilibrium toward p66
homodimer formation compared to His-p66 incubated in the
absence of drug (Figure 1). TMC120 and TMC125 also
enhanced p66 homodimerization, although the extent to
which the p66 monomer was converted to the p66 homo-
dimer was not as complete as for EFV, since detectable levels
of monomers were observed. In contrast, NVP showed the
weakest capacity to enhance p66 homodimerization. These
data demonstrate that EFV, TMC120, and TMC125 are more
potent enhancers of p66 homodimerization compared to
NVP.
EFV Increases Homodimerization of a Model Pol Construct
in the Yeast Two-Hybrid System
To determine whether EFV promotes homodimerization of
a polyprotein expressing p66 we used the yeast two-hybrid
(Y2H) system to assess the effect of EFV on the interactions
between ‘‘bait’’ and ‘‘prey’’ fusion constructs expressing a
previously described 90-kDa model Pol construct comprising
the C-terminus of nucleocapsid (NC), the transframe region,
PR, RT, and the first 44 amino acids of IN [31,32]. The model
Pol used in these experiments contains a PR active site
mutation so that the bait and prey polyproteins are not
Figure 1. NNRTI Enhancement of p66 Homodimer Formation In Vitro
The effect of NNRTIs on the p66 monomer-homodimer equilibrium was
determined by incubating His-p66 in the absence and presence of a 10-
fold molar excess of drug relative to total protein for 2 h at 4 8C followed
by analysis of the quaternary structure by SEC.
doi:10.1371/journal.ppat.0020119.g001
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Synopsis
HIV-1 encodes reverse transcriptase (RT), an enzyme that is essential
for virus replication. Nonnucleoside reverse transcriptase inhibitors
(NNRTIs) are allosteric inhibitors of the HIV-1 RT. In HIV-1-infected
cells NNRTIs block the RT-catalyzed synthesis of a double-stranded
DNA copy of the viral genomic RNA, which is an early step in the
virus life cycle. Potent NNRTIs have the novel feature of promoting
the interaction between the two RT subunits. However, the
importance of this effect on the inhibition of HIV-1 replication has
not been defined. In this study, the authors show that potent
NNRTIs block an additional step in the virus life cycle. NNRTIs
increase the intracellular processing of viral polyproteins called Gag
and Gag-Pol that express the HIV-1 structural proteins and viral
enzymes. Enhanced polyprotein processing is associated with a
decrease in viral particles released from NNRTI-treated cells. NNRTI
enhanced polyprotein processing is likely due to the drug binding
to RT, expressed as part of the Gag-Pol polyprotein and promoting
the interaction between separate Gag-Pol polyproteins. This leads to
premature activation of the Gag-Pol embedded HIV-1 protease,
resulting in a decrease in full-length viral polyproteins available for
assembly and budding from the host cell membrane. This study
provides proof-of-concept that small molecules can modulate the
interactions between Gag-Pol polyproteins and suggests a new
target for the development of HIV-1 antiviral drugs.
proteolyzed by the embedded HIV-1 PR. In the absence of
drug, the interaction between the Pol-bait and Pol-prey
fusions was weak as assessed by measuring b-galactosidase (b-
gal) activity. In contrast, when yeast expressing the Pol-bait
and Pol-prey fusions were cultured in the presence of
increasing concentrations of EFV we observed a dose-
dependent increase in b-gal activity which increased 5-fold
compared to the untreated control in the presence of 15 lM
EFV (Figure 2). Yeast co-transformed with either the Pol-bait
and the empty prey plasmid or the Pol-prey and the empty
bait plasmid and grown in the absence or presence of EFV did
not demonstrate detectable levels of b-gal activity, indicating
lack of self-activation of the reporter gene by the model Pol
fusion proteins in yeast. These data demonstrate that EFV
mediates a concentration-dependent increase in the inter-
action between two separate model Pol proteins indicating
that EFV can promote interactions between p66 RT express-
ing polyproteins.
EFV, TMC120, and TMC125 Increase Intracellular Gag-Pol
Processing
Since EFV enhances homodimerization of p66 and the
model Pol polyprotein, we hypothesized that potent NNRTIs
can enhance Gag-Pol/Gag-Pol interactions resulting in in-
creased processing of Gag-Pol due to premature activation of
the HIV-1 PR. To investigate this hypothesis we analyzed the
intracellular viral protein profile of pDRNL-transfected 293T
cells treated with NNRTIs. The concentrations of NNRTIs
tested were not cytotoxic (unpublished data) as determined
by the CellTiter 96 aqueous non-radioactive cell proliferation
assay (Promega, Madison, Wisconsin, United States). Cells
treated with EFV, TMC120, and TMC125 demonstrated
reduced levels of Pr160gag-pol compared to untreated cells as
determined by quantitative Western blot analysis using RT
antibodies (Figure 3A). The relative levels of the Gag-Pol
processing intermediates p107 (PR-RT-IN) and p76 (PR-RT)
were increased compared with p120 (NC-p6-PR-RT-IN), p113
(p6-PR-RT-IN), and p97 (RT-IN) in cells treated with EFV,
TMC120, and TMC125 (Figure 3A). These processing inter-
mediates have previously been observed in HIV-1-infected
cells [33]. Significantly, we observed a 2- to 2.7-fold increase
in the levels of p51 RT with respect to p66 RT in cells treated
with EFV, TMC120, and TMC125 compared to the untreated
controls (Figure 3A and 3B). In contrast, no significant
difference was observed in the Pr160gag-pol processing pattern
in cells treated with DLV, NVP, and the nucleoside reverse
transcriptase inhibitor, zidovudine (AZT), indicating that
enhanced Gag-Pol processing is a property of potent NNRTIs.
EFV, TMC120, and TMC125 Enhance Intracellular Gag
Processing
If enhanced processing of Pr160gag-pol by EFV, TMC120,
and TMC125 is due to increased levels of HIV-1 PR activity in
the cell, we would expect to see increased processing of Gag.
Quantitative Western blot analysis of cell lysates probed with
p24 antibodies demonstrated a 3.2- to 3.9-fold increase in the
p24 to Pr55gag ratio in cells treated with EFV, TMC120, and
TMC125 compared to untreated cells and cells treated with
NVP, DLV, and AZT (Figure 3C and 3D). We also observed an
increase in total Gag in cells treated with potent NNRTIs
suggesting an accumulation of Gag inside the cell. However,
consistent with enhanced processing of Pr55gag, we found
that the ratio of intracellular Pr55gag to total Gag (including
the processing intermediates and p24) in cells treated with
potent NNRTIs was 50% of untreated cells or cells treated
with the other inhibitors (unpublished data). Paradoxically,
we observed an increase in the steady-state levels of the p41
and p25 Gag processing intermediates in cells treated with
EFV, TMC120, and TMC125, suggesting an additional effect
on Gag processing by these NNRTIs. No significant change in
the Gag processing pattern was observed in cells treated with
NVP, DLV, and AZT with the p24 to Pr55gag ratios
comparable to untreated cells (Figure 3C and 3D). Taken
Figure 2. Effect of EFV on a Model Pol Construct in the Y2H System
Yeast strain CTY10-5d expressing a model Pol construct as both bait and
prey was assayed for b-gal activity in the presence of EFV. Results are
expressed as fold increase in b-gal activity compared to the untreated
control. Data represent at least three independent assays and are
expressed as the mean 6 standard error.
doi:10.1371/journal.ppat.0020119.g002
Figure 3. EFV, TMC120, and TMC125 Enhance Intracellular Gag and Gag-
Pol Processing
293T cells were transfected with pDRNL and treated with 5 lM of each
drug. After 36 h post-transfection, cell lysates were harvested and viral
proteins were detected by quantitative Western blot analysis using (A)
anti-RT and (C) anti-CA antibodies. AlexFluor680 goat anti-mouse was
used as the secondary antibody. Western blots were scanned on an
Odyssey Infrared Imager and analyzed using Odyssey software.
Quantitation of the intracellular ratio of (B) p51 to p66 and (D) p24 to
Pr55Gag. The ratios were calculated from at least three independent
experiments and are expressed as the mean 6 standard error.
doi:10.1371/journal.ppat.0020119.g003
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together, these data demonstrate that NNRTIs that enhance
p66 homodimerization can enhance the intracellular pro-
cessing of both HIV-1 Gag and Gag-Pol polyproteins.
EFV Demonstrates No Significant Effect on Virion Gag and
Gag-Pol Processing Patterns
To investigate whether the Gag and Gag-Pol processing
patterns were also altered in the virus, Western blot analysis
was performed on virions released from HIV-1-transfected
293T cells treated with EFV. In contrast to viral proteins in
cell lysates, we observed no significant change in the
processing pattern of Gag and Gag-Pol in virions from
EFV-treated cells compared to untreated cells and cells
treated with NVP and AZT. Specifically, we detected no
change in the ratios of p24 to Pr55gag (Figure 4A and 4B) and
p51 RT to p66 RT (Figure 4C and 4D) in EFV-treated cells
compared to untreated controls. These data suggest that
enhanced viral polyprotein processing by these drugs are
more apparent in the cell rather than in the virion. In
contrast, we observed reduced levels of virus produced from
cells treated with EFV compared to untreated cells and cells
treated with NVP and AZT (Figure 4A and 4C) suggesting that
EFV may affect viral particle production.
Enhanced Gag and Gag-Pol Processing Observed in a
Myristoylation Defective Mutant
Our data demonstrate that EFV, TMC120, and TMC125
enhance intracellular Gag and Gag-Pol processing while no
significant effect on viral protein processing was detected in
the virion in the presence of EFV. To determine whether
enhanced processing of Gag and Gag-Pol requires Gag/Gag-
Pol localization to the plasma membrane, 293T cells were
transfected with pGA2-NL4.3, a myristoylation-defective
(myr-) HIV-1 mutant, in the presence of NNRTIs.
Previous studies have shown that myristoylation of HIV-1
Gag is essential for viral assembly and budding at the plasma
membrane [34]. Prevention of myristoylation by introduction
of a glycine to alanine substitution at the second amino acid
in Gag results in the accumulation of Gag and Gag-Pol in cells
and no detectable release of viral particles [34]. We observed
a dramatic increase in intracellular processing of Pr55gag to
p24 (6- to 7.5-fold) and p66 RT to p51 RT (2.0- to 3.3-fold) in
cells treated with EFV, TMC120, and TMC125 compared to
untreated cells and cells treated with NVP (Figure 5). A faint
band corresponding to Gag-Pol was observed in untreated
cells and cells treated with NVP, but not in cells treated with
potent NNRTIs, consistent with enhanced Gag-Pol processing
by potent NNRTIs (unpublished data). A similar enhance-
ment of intracellular Gag and Gag-Pol processing was also
observed in HeLa cells treated with potent NNRTIs (unpub-
lished data). As expected, we observed 100% inhibition of
viral particle production by Western blot analysis in the
culture supernatant of cells transfected with the myr(-)
mutant (unpublished data). Enhanced Gag and Gag-Pol
processing in cells treated with potent NNRTIs and trans-
fected with either wild-type or the myr(-) HIV-1 mutant
support the notion that these drugs enhance viral protein
processing within the cell.
Inhibition of Viral Particle Production in the Presence of
EFV, TMC120, and TMC125
We have demonstrated that potent NNRTIs can increase
intracellular processing of Gag and Gag-Pol, which is
consistent with enhanced HIV-1 PR activity in the cell. One
consequence of enhanced intracellular processing of Gag and
Gag-Pol is that less viral polyproteins are available for
assembly and budding from the cell, leading to a decrease in
viral particle production. Enhanced Gag and Gag-Pol process-
ing and a block in viral particle production has previously been
observed when either Gag-Pol is overexpressed or expressed as
a linked PR dimer in cells [6,35]. To explore this possibility,
viral proteins were pulse-labeled with Trans[35S]-label in HIV-
1-transfected 293T cells to measure viral particle output. EFV
treatment resulted in a reduction in virion-associated p24 with
the most significant decrease at 5 lM of drug (45% decrease
compared to no drug) (Figure 6A and 6B). A similar reduction
in viral particles released from cells treated with 5 lM of
TMC120 (44% decrease) and 5 lM of TMC125 (33% decrease)
was also observed. In contrast, levels of virion-associated p24
from cells treated with NVP or DLV were similar to untreated
cells. Reduced viral particle production (60% decrease) was
also observed in HIV-1-transfected HeLa cells treated with
EFV (Figure 6C and 6D). These data suggest that the enhance-
ment of intracellular viral protein processing mediated by
potent NNRTIs leads to a reduction in viral particle
production from HIV-1-transfected cells.
Decreased Viral Particle Production in Cells Treated with
EFV Is Dependent on a Functional HIV-1 PR
The association between decreased viral particle produc-
tion and enhancement of intracellular Gag and Gag-Pol
Figure 4. EFV Does Not Effect Virion Protein Processing
Viral particles were pelleted from pDRNL-transfected 293T cells treated
with 5 lM of each drug, and the Gag and Gag-Pol processing patterns
were analyzed by quantitative Western blotting using (A) anti-CA and (C)
anti-RT antibodies. Quantitation of the ratio of (B) p24 to Pr55Gag and (D)
p51 to p66 from Western blots. The ratios were calculated from at least
three independent experiments and are expressed as the mean 6
standard error.
doi:10.1371/journal.ppat.0020119.g004
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processing suggests that EFV promotes the premature
activation of the HIV-1 PR in the cell. Hence, inactivating
the viral PR would be expected to negate the effect of EFV on
viral particle production. To examine this possibility, 293T
cells were transfected with PR(-)pNL4.3, which contains an
active site mutation (D25A) in the HIV-1 PR, in the absence
and presence of NNRTIs [34]. As expected, the PR(-) mutant
released immature viral particles expressing Pr55gag (Figure
7A and 7C) and Pr160gag-pol (unpublished data). In cells
treated with EFV, no significant reduction in viral particle
output was observed, compared to untreated cells and cells
treated with NVP (Figure 7A and 7C). These data demonstrate
that inhibition of virus production by EFV is dependent on a
functional HIV-1 PR.
EFV Does Not Inhibit Viral Production of EFV-Resistant
HIV-1
Our previous studies suggest a correlation between
enhancement of p66 homodimerization by EFV and its
capacity to increase the processing kinetics of a model HIV-
1 Pol construct [31]. Since p66 RT is expressed as part of the
Gag-Pol polyprotein, we investigated whether EFV mediates
its effect on viral particle production by binding to the p66
subunit in the context of Gag-Pol. 293T cells were transfected
with K103NpNL4.3, which expresses the K103N mutation in
the RT that confers resistance to EFV by preventing drug
binding to the HIV-1 RT [36]. In cells treated with EFV, no
significant reduction in viral particle production was ob-
served compared to untreated cells and cells treated with
NVP (Figure 7B and 7D). These data suggest that in order for
EFV to inhibit viral particle production it must bind to p66
RT in the context of Gag-Pol.
EFV Has No Effect on Viral Particle Production of Moloney
Murine Leukemia Virus
NNRTIs are highly specific to the HIV-1 RT, and therefore
effects on viral particle production by EFV should be specific
to HIV-1-transfected cells [15]. To confirm that EFV does not
affect viral particle production of other retroviruses, 293T
cells were transfected with an infectious molecular clone of
Moloney murine leukemia virus (Mo-MuLV) in the presence
of drug. We found no difference in viral particle production
for EFV- and NVP-treated cells compared to the no-drug
control (Figure 8). These data demonstrate that the effect of
EFV on viral particle output is specific and not due to
cytotoxicity mediated by this lipophillic NNRTI.
Discussion
In this study, we report that potent NNRTIs EFV, TMC120,
and TMC125 enhance p66 RT homodimerization and that
this property correlates with the capacity of these NNRTIs to
inhibit the late stages of HIV-1 replication. This effect was
not observed with NVP, which has little effect on p66
homodimerization in vitro, or with AZT, a drug that belongs
to the separate nucleoside analog class of RT inhibitors. EFV
Figure 6. Potent NNRTIs Inhibit Viral Particle Production
Viral particle production in drug-treated 293T cells (A) and in HeLa cells
(C). Top panels represent virion-associated p24 and bottom panels are
p24 present in cell lysates. Cells were transfected with pDRNL and
treated with drug as described in Figure 3, except that after 36 h, cells
were metabolically labeled with Trans[35S]-label for 4 h. Cell lysates were
immunoprecipitated using anti-CA mAb and viral particles in the
supernatant were pelleted through a sucrose cushion. The proteins
were separated by SDS-PAGE and visualized and quantified using a
phosphorimager. Viral particle production in 293T cells (B) and HeLa cells
(D) was quantified as described in Materials and Methods. Data represent
at least three independent experiments and are expressed as the mean
6 standard error.
doi:10.1371/journal.ppat.0020119.g006
Figure 5. Increased Viral Protein Processing by Potent NNRTIs Is
Independent of Gag/GagPol Localization to the Plasma Membrane
Cells were treated as described in Figure 3, except for transfection with
pGA2-NL4.3, which expresses a myr(-) defective mutant of HIV-1. All
drugs were tested at 5 lM. Cell lysates harvested after 36 h were
analyzed by quantitative Western blotting using (A) anti-RT and (C) anti-
CA. Quantitation of the ratio of (B) p51 to p66 and (D) p24 to Pr55gag
from Western blots was performed using the Odyssey system. The ratios
were calculated from at least three independent experiments and are
expressed as the mean 6 standard error.
doi:10.1371/journal.ppat.0020119.g005
PLoS Pathogens | www.plospathogens.org November 2006 | Volume 2 | Issue 11 | e1191055
Potent NNRTIs Target HIV-1 Gag-Pol
promoted homodimerization of a model Pol construct in the
Y2H system, indicating that this drug binds to p66 in the
context of a larger Pol polyprotein. Pol multimerization,
leading to HIV-1 PR homodimerization and its activation, is
the likely mechanism for our previous data demonstrating
that EFV enhances processing of a model Pol polyprotein
[31]. Potent NNRTIs also enhanced intracellular processing of
Gag-Pol and Gag, and this correlated with reduced viral
particle production. In addition, enhanced polyprotein
processing did not require localization of Gag/Gag-Pol to
the plasma membrane. The effect was dependent on a
functional HIV-1 PR, as EFV did not decrease viral particle
production in cells transfected with a PR(-) mutant of HIV-1.
EFV also failed to decrease viral particle production of HIV-1
expressing the K103N mutation in the RT gene that confers
EFV resistance indicating that the effect is specific to the drug
binding to the HIV-1 RT in the context of Gag-Pol. We
observed no evidence of cytotoxicity at the drug concen-
trations tested, and consistent with this observation we found
that EFV did not reduce the output of Mo-MuLV particles
from 293T cells. Therefore, in addition to the established
effects of NNRTIs on inhibiting HIV-1 RT enzyme function at
an early step in the virus life cycle, our data demonstrate that
potent NNRTIs target the late stages of HIV-1 replication and
that Gag-Pol multimerization is an effective target for the
development of small molecule inhibitors against HIV-1.
What is the mechanism of increased HIV-1 polyprotein and
reduced viral particle production in cells treated with highly
potent NNRTIs? Our data are consistent with the explanation
that potent NNRTIs specifically bind to p66 in the context of
Gag-Pol in the cytoplasm of the cell, thereby promoting Gag-
Pol/Gag-Pol interactions leading to premature activation of
the HIV-1 PR. The PR cleaved from Gag-Pol is then available
for cleavage of Gag, explaining why the effect on processing
was not confined to Gag-Pol. The ultimate consequence of
enhanced intracellular processing of Gag and Gag-Pol is that
there are less unprocessed polyproteins in the cell available
for assembly and budding at the plasma membrane leading to
a reduction in viral particle production. Premature activation
of the HIV-1 PR leading to a block in viral particle
production has been previously described when either Gag-
Pol is overexpressed [6] or expressed as a linked PR dimer in
cells [35]. Our study demonstrates for the first time that a
small molecule inhibitor can enhance HIV-1 polyprotein
processing, leading to inhibition of viral particle production.
In addition, our study underscores the importance of the RT
domain and its propensity to dimerize in promoting Gag-Pol/
Gag-Pol interactions and activation of the HIV-1 PR.
The levels of enhancement of intracellular Gag and Gag-
Pol processing as quantified by the increase in ratios of p24 to
Pr55gag (for Gag) and p51 RT to p66 RT (for Gag-Pol) were in
the range of 3.2- to 3.9-fold and 2- to 2.7-fold, respectively.
The decrease in viral particle output for potent NNRTIs in
the same cells as determined by pulse-labeling (Figure 6) was
33%–44%. Calculation of the enhancement of processing
relies on the assumption that antibody detection of precursor
and processing products are equivalent on a molar level. This
could account for the slightly greater effects observed for
polyprotein processing compared to viral particle output.
Nevertheless, our data are consistent with the assertion that
NNRTI enhancement of Gag and Gag-Pol processing is
associated with a decrease in viral particle production.
While we observed increased intracellular processing of
Gag and Gag-Pol in the presence of potent NNRTIs, this effect
was not detected in viral particles that were released in the
culture supernatant. Our experiments with a myr (-) HIV-1
mutant clearly demonstrated a dramatic effect on enhanced
processing of Pr55gag to p24 and p66 RT to p51 RT in 239T
and HeLa cells treated with EFV, TMC120, and TMC125
compared to untreated cells. These data indicate that
enhanced polyprotein processing occurs in the absence of
Gag and Gag-Pol localization to the plasma membrane as
previously described for myr (-) mutants of HIV-1 [34].
The impact of potent NNRTIs on the inhibition of viral
particle production was observed at concentrations of
inhibitor (5 lM) that are two to three orders of magnitude
higher than levels required to inhibit HIV-1 replication in
cell culture based assays (0.001–0.084 lM) [15,23,25]. Never-
theless, the median plasma levels of EFV in drug-treated
individuals is 7 lM indicating that the effect of the drug is at
physiological concentrations [37]. Furthermore, the intra-
cellular concentrations of EFV in peripheral blood mono-
nuclear cells from drug-treated patients are similar to the
total plasma concentrations of the drug [38]. Therefore, it is
possible that affects on the late stage of HIV-1 replication
may contribute in part to the inhibitory activity of these
drugs in vivo, although this remains to be determined.
The large differences in potency of the drugs for inhibition
of RT compared to viral particle production can be explained
by the relative affinity of the drugs for the mature RT
heterodimer and the proposed target for the late effect, p66
RT in the context Gag-Pol. While the structure of the NNRTI
binding site is well characterized in the RT heterodimer, its
Figure 7. Inhibition of Viral Particle Production by EFV Is Dependent on a
Functional HIV-1 PR and Is Mediated by the Drug Binding to p66 RT
293 T cells were transfected with (A) PR(-)pNL4.3 that contains an active
site mutation in the HIV-1 PR or (B) K103NpNL4.3 that prevents EFV
binding to RT. Cells were transfected and treated with Trans[35S]-label as
described in Figure 6. Top panels represent virion-associated Gag or p24
and bottom panels represent Gag or Gag processing products present in
cell lysates. Quantitation of viral particle production in 293T cells
transfected with (C) PR(-)pNL4.3 and (D) K103NpNL4.3. Data represent at
least three independent experiments and are expressed as the mean 6
standard error.
doi:10.1371/journal.ppat.0020119.g007
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structure in the context of the Gag-Pol polyprotein is
unknown. It is possible that while potent NNRTIs can bind
to p66 in Gag-Pol, the binding is weaker than its interaction
with the RT heterodimer, thereby explaining the requirement
for much higher concentrations of drug to observe an effect
on viral particle production compared to inhibition of RT
activity.
In cells treated with potent NNRTIs we observed enhanced
processing of Pr55gag to p24 CA. Paradoxically, we also
observed evidence of less efficient processing of Gag by the
presence of an accumulation of the p41 and p25 Gag
processing intermediates, which is reminiscent of a p6 late
domain defect [39]. An accumulation of total Gag was also
observed in cells treated with potent NNRTIs consistent with
a decrease in viral particle output. The first cleavage in Gag is
between p2/NC, which would release the p6 late domain that
is required for viral particle egress from the cell [40]. It is
possible that a proportion of Gag molecules that have
reached the plasma membrane lack p6, thus conferring a
late domain effect. Electron microscopy analysis of EFV-
treated HeLa cells demonstrated a reduction in viral particle
production compared to untreated cells and a higher
proportion of immature particles attached to the plasma
membrane (unpublished data). These were generally single
immature particles with stalks still attached to the plasma
membrane, which were few in number but still greater in
EFV-treated compared to untreated cells. While the main
defect we observed both by electron microscopy and
biochemical analyses was a reduction in viral output, our
data also suggest a secondary late domain defect, which could
be attributed to enhanced Gag processing by potent NNRTIs.
This is the first report of small molecule inhibitors that can
inhibit assembly and viral particle production by mediating
enhanced intracellular processing of the HIV-1 Gag and Gag-
Pol polyproteins. In contrast, there are several reports of
small molecules or peptides that decrease virus processing
and maturation, including the HIV-1 PR inhibitors [41,42], a
12-mer peptide that targets the CA domain of Gag [43], CAP-
1, which targets CA [44], and 3-O-(39,39-dimethylsuccinyl)-
betulinic acid (DSB) which targets the cleavage of the CA
precursor resulting in a block in viral core condensation
[45,46]. Our studies provide proof-of-concept that a small
molecule inhibitor can induce premature processing of Gag
and Gag-Pol in the cell. The development of screens to detect
agents that enhance Gag-Pol/Gag-Pol interactions may lead to
the identification of more potent inducers of premature
processing of HIV-1 polyproteins. Such a screen could be
enhanced by incorporating mutations in the RT that are
known to confer resistance to the current NNRTIs in order to
select for agents that will be active against drug resistant
strains. Furthermore, these potent NNRTIs can be used as
probes to dissect the role of Gag-Pol multimerization in HIV-1
PR activation and viral assembly.
Materials and Methods
Drugs and reagents. EFV, NVP, and AZT were obtained from the
AIDS Research and Reference Reagent Program, National Institute of
Allergy and Infectious Diseases, National Institutes of Health. DLV
was purchased from Biomol (Plymouth Meeting, Pennsylvania, United
States). TMC120 and TMC125 were supplied by Tibotec Pharma-
ceuticals (Mechelen, Belgium). The HIV-1 RT monoclonal antibody
(mAb) 11G10 was provided by Dag Helland (University of Bergen,
Norway) [47]. MAb to HIV-1 capsid (p24) was obtained from the NIH
AIDS Research and Reference Reagent Program (contributed by B.
Chesebro). Mo-MuLV CA antibody (NCI Number 79S-804) was
provided by S. Goff (Columbia University, New York, United States).
SEC. Recombinant p66 expressed with an N-terminal His-p66 was
purified by Ni-NTA and DEAE-Sepharose chromatography as
previously described. His-p66 was diluted in running buffer (50
mM sodium phosphate [pH 7.8] and 150 mM NaCl) to a final
concentration of 3.8 lM in the absence and presence of a 10-fold
molar excess of NNRTI relative to total protein. Protein was
resolved by SEC after 2 h incubation on ice using a Superdex 200
column (Amersham Biosciences, Little Chalfont, United Kingdom)
and fast protein liquid chromatography (FPLC) as previously
described [31].
DNA plasmid constructs. The plasmid pDRNL contains the NL4.3
infectious molecular clone of HIV-1 [48]. The plasmid pNCS,
containing the infectious Mo-MuLV clone, was kindly provided by
S. Goff.
PR(-)pNL4–3, which expresses the D25N PR active site mutation,
was constructed as previously described [49]. K103NpNL4.3, ex-
pressing the K103N mutation in the RT gene, was constructed by
PCR stitch mutagenesis. Primers F1-sense (59-GCTTCAGGTTTGGG-
GAAGAG-39) and F1-antisense (59-CCAGTACTGTTACT-
GATTTGTTCTGTTTTAACCCTGCAGGATGTGG-39) were used to
amplify a 700-bp F1 fragment. Primers F2-sense (59-GCAGGGT-
TAAAACAGAACAAATCAGTAACAGTACTGGATGTGGGCG-39)
and F2-antisense (59- GCTACACTGGAATATTGC-39) were used to
amplify a 200-bp F2 fragment. F1 and F2 fragments were joined by
PCR extension as previously described. The resulting amplimers
were cloned into the Bcl I and Bst Z171 sites of pDRNL. The pGA2-
NL4.3 clone expressing the G2A mutation in HIV-1 Gag was
generated by stitch PCR. The primers F3-sense (59-GGAGAGA-
GATGGTTGCGAGAGCGTCGGTATTAAGCG-39) and F3-antisense
(59-TTTGGTCCTTGTCTTATGTCCAGAATGC-39) were used to am-
plify an 878-bp fragment. Primers F4-sense (59-CTCTAG-
CAGTGGCGCCCGAACAGGGAC-39) and F4-antisense (59-
CGACGCTCTCGCAACCATCTCTCTCCTTCTAGCC-39) were used
to amplify a 182-bp fragment. The PCR fragments were joined by
PCR extension and then cloned into the BssH II and Spe I sites in
pDRNL. The Y2H constructs pGADNOT-Pol and pSH2–1-Pol
express a previously described model 90-kDa HIV-1 Pol polyprotein
[32]. The region representing the model Pol (corresponding to
nucleotides 2083–4367 of HXB2) was amplified by PCR from
pGEM:Pol using the primers 59pol-B (59-GTCGACTTATTTTAGCT-
GACATTTATC-39) and 39pol-B (59-GGATCCAAGCCAACTTTTT-
TAGGGAAG-39). The Bam HI-Sal I digested amplimers were
cloned into the corresponding sites in pSH2–1 [50] and pGADNOT
[50] to yield pGADNOT-Pol and pSH2–1-Pol, respectively. For all
constructs, the introduced mutation was confirmed by sequencing
and no spontaneous mutations were detected.
Cell culture and transfection. 293T and HeLa cells were main-
tained in Dulbecco’s modified Eagle medium containing 10% fetal
calf serum (DMEM-10). Cells (2 3 106) were seeded into 10 cm in
diameter tissue culture plates 24 h before transfection. Cells were
transfected with 10 lg of HIV-1 or Mo-MuLV plasmid and 2 lg of
pEGFP (expressing enhanced fluorescent green protein) using a
Figure 8. Effect of EFV on Mo-MuLV Particle Production
293 T cells were transfected with Mo-MuLV proviral DNA and treated as
described in Figure 6, except that cell lysates were immunoprecipitated
with a Mo-MuLV CA antibody. All drugs were tested at 5 lM. Viral particle
production was quantified as described in Materials and Methods. Data
represent at least three independent experiments and are expressed as
the mean 6 standard error.
doi:10.1371/journal.ppat.0020119.g008
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calcium phosphate procedure as previously described [51]. Cells were
pretreated with drug immediately prior to transfection and drugs
were maintained in the culture up to the time of harvesting cells and
culture supernatant.
Preparation of viral and cell lysates. At 36 h post-transfection, cell-
free culture supernatants were collected and centrifuged through a
20% w/v sucrose cushion (100,000g, 1 h, 4 8C) using a SW41 rotor
(Beckman L-90 ultracentrifuge, Fullerton, California, United States).
Viral pellets were solubilized in 80 ll of 2X sodium dodecyl sulfate
(SDS) loading buffer and heated to 95 8C for 3 min prior to Western
blot analysis [51]. Cells were washed in ice-cold phosphate buffered
saline without magnesium and calcium PBS(-) and centrifuged
(1,000g, 5 min, 4 8C). Pellets were lysed in 500 ll TNEN buffer (55
mM Tris [pH 8.0], 75 mM NaCl, 10 mM EDTA, 0.5 % IGEPAL, 1.0 lg/
ml leupeptin, 1.0 lg/ml aprotinin, 1.0 lg/ml pepstatin) for Western
blot analysis or in 500 ll RIPA buffer (150 mM NaCl, 1.0% IGEPAL,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris [pH 8.0], 1.0 lg/ml
leupeptin, 1.0 lg/ml aprotinin, 1.0 lg/ml pepstatin) for immunopre-
cipitation. Cell debris was removed by centrifugation (20,000g, 20
min, 4 8C) and clarified lysate was mixed with equal volumes of 2X
SDS sample buffer and boiled. Virion- and cell-associated viral
proteins, normalized for equivalent levels of EGFP, were resolved on
a 10% SDS-polyacrylamide (SDS-PAGE) gel. Resolved proteins were
transferred to Hybond C-extra (Amersham) followed by quantitative
Western blot analysis.
Quantitative Western blot analysis. Quantitative Western blot
analysis was performed using the Odyssey Infrared Imaging System
according to manufacturer’s instructions (LI-COR, Lincoln, Nebras-
ka, United States). For detection, membranes were blocked with a 1:1
v/v of Odyssey buffer (LI-COR) and PBS(-) for 1 h at room
temperature followed by a 1-h incubation with anti-HIV CA p24
mAb or anti-RT 11G10 mAb diluted 1:500 and 1:100, respectively in
Odyssey buffer containing 0.2% Tween 20. Membranes were washed
in PBS(-) containing 0.1% Tween 20 and incubated for 1 h with a
1:10,000 dilution of AlexaFluor 680 goat anti-mouse IgG (Molecular
Probes, Eugene, Oregon, United States) in Odyssey buffer containing
0.2% Tween 20 and 0.02% SDS. Viral proteins were visualized using
the Odyssey Infrared Imager (LI-COR) and molecular analysis of band
intensities was quantified using the Odyssey Application Software
Version 1.2 (LI-COR) by measuring the integrated intensity (I.I) (also
referred to as pixel volume). I.I is proportional to the amount of dye-
labeled antibodies bound to the membrane.
Viral particle production. At 36 h post-transfection, cells were
starved for 30 min in DMEM lacking methionine and cysteine
followed by a 4-h pulse with 125 lCi of Trans[35S]-label per ml (1175.0
Ci/mmol, PerkinElmer, Wellesley, California, United States) in the
presence and absence of drug. After radio-labeling, viral particles
were pelleted through a 20% w/v sucrose cushion and cells were
collected, washed with PBS(-), and lysed in RIPA buffer. Cell extracts
were immunoprecipitated with 5 lg of p24 mAb and 20 ll of Protein
G PLUS agarose (Santa Cruz Biotechnology, Santa Cruz, California,
United States). Virion proteins were resolved by 10% SDS-PAGE, and
the band intensities quantified using the Bio Imaging Analyzer (Fuji
Photo Film Company, Tokyo, Japan). Virus production was calculated
as the amount of virion-associated Gag (p55þp24/p25) divided by the
total (cell and virion) Gag [52].
Yeast two-hybrid assay. The yeast strain, CTY10-5d, was trans-
formed with ‘‘bait’’ and ‘‘prey’’ constructs as previously described
[53]. Quantitation of protein–protein interactions was determined by
measuring b-gal activity in yeast lysates from at least three
independent transformants using ortho-nitrophenyl-D-galactopyrano-
side (ONPG) as the substrate, as previously described [53].
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